To identify new biomarkers and mechanisms associated with RTKi resistance in EML4-ALK rearranged NSCLC and to develop treatment strategies, we established resistance cell lines against the second-generation ALK inhibitor, ceritinib. This evidence concerns the gene EML4 and non-small cell lung carcinoma.